These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8416600)

  • 21. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB; Stephenson G; Ben Shachar D
    Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxidative stress: a role in the pathogenesis of Parkinson's disease.
    Götz ME; Freyberger A; Riederer P
    J Neural Transm Suppl; 1990; 29():241-9. PubMed ID: 2193108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoradiography of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): uptake in the monoaminergic pathways and in melanin containing tissues.
    Lydén A; Bondesson U; Larsson BS; Lindquist NG; Olsson LI
    Acta Pharmacol Toxicol (Copenh); 1985 Aug; 57(2):130-5. PubMed ID: 3877403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.
    Gerlach M; Double KL; Ben-Shachar D; Zecca L; Youdim MB; Riederer P
    Neurotox Res; 2003; 5(1-2):35-44. PubMed ID: 12832223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuromelanin: a role in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Life Sci; 1987 Feb; 40(8):705-12. PubMed ID: 2880274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for a glycidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra.
    Aime S; Fasano M; Bergamasco B; Lopiano L; Valente G
    J Neurochem; 1994 Jan; 62(1):369-71. PubMed ID: 8263538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease.
    Offen D; Ziv I; Barzilai A; Gorodin S; Glater E; Hochman A; Melamed E
    Neurochem Int; 1997 Aug; 31(2):207-16. PubMed ID: 9220453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture.
    Snyder SH; D'Amato RJ
    Neurology; 1986 Feb; 36(2):250-8. PubMed ID: 3080696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p-Quinone mediates 6-hydroxydopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly.
    Izumi Y; Sawada H; Sakka N; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
    J Neurosci Res; 2005 Mar; 79(6):849-60. PubMed ID: 15712215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.
    Jellinger KA
    Drugs Aging; 1999 Feb; 14(2):115-40. PubMed ID: 10084365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease.
    Zhang F; Dryhurst G
    J Med Chem; 1994 Apr; 37(8):1084-98. PubMed ID: 7909337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study.
    Shima T; Sarna T; Swartz HM; Stroppolo A; Gerbasi R; Zecca L
    Free Radic Biol Med; 1997; 23(1):110-9. PubMed ID: 9165303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease.
    Cai W; Wakamatsu K; Zucca FA; Wang Q; Yang K; Mohamadzadehonarvar N; Srivastava P; Tanaka H; Holly G; Casella L; Ito S; Zecca L; Chen X
    Prog Neurobiol; 2023 Apr; 223():102414. PubMed ID: 36746222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanin affinity and its possible role in neurodegeneration.
    Karlsson O; Lindquist NG
    J Neural Transm (Vienna); 2013 Dec; 120(12):1623-30. PubMed ID: 23821370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuromelanin synthesis in rat and human substantia nigra.
    Rabey JM; Hefti F
    J Neural Transm Park Dis Dement Sect; 1990; 2(1):1-14. PubMed ID: 2357268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
    Kastner A; Hirsch EC; Lejeune O; Javoy-Agid F; Rascol O; Agid Y
    J Neurochem; 1992 Sep; 59(3):1080-9. PubMed ID: 1494900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies.
    Fasano M; Bergamasco B; Lopiano L
    J Neural Transm (Vienna); 2006 Jun; 113(6):769-74. PubMed ID: 16755381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.